Global Burden of Disease Study

It was published.

in the Global Burden of Disease Report that came out for 2019, published a year later.

And the reason is that migraine isn't just a headache, right? It's a brain disease.

And part of the reason is that the impact on you isn't just the pain, it's the brain fog that y'all were talking about.

It's in a very prominent medical journal, the Journal of Headache and Pain.

It was published in 2020.

And these are findings from the Global Burden of Disease Report in 2019.

So they look at a lot of different measures of how disease is impacting people's lives all over the world.

And because it kills quietly, over weeks, in places where death is already common.

The Global Burden of Disease Study excludes it from the meningitis count, so the official number of 2 in 36,000 deaths a year is an undercount.

The real burden is probably closer to 400,000.

That's a city a year.

28 million women in America alone have migraines.

The Global Burden of Disease report found that migraine is the leading cause of disability in women under 50.

That was first reported in 2020.

That means that migraine is more likely to take you away from the life you love than any other disease.

So I think one thing that people don't know is that migraine is actually the leading cause of disability in women under 50.

Now, this is according to the Global Burden of Disease Report.

And so this is looking at very, very large swaths of people.

I think we can hang our hat on this data.

US 1990 by Vintage.

GK 2022-GBD 2021 ish 26.16216877%.

GK 2023-26.16191548%.

GK 2024-GBD 2023 ish 27.41027501%.

It's a pleasure to be here and thank you for having me.

We have used the Global Burden of Disease, it's known as GBD typically, stillbirth estimation framework for our publication.

The GBD approach is quite sophisticated statistically, but the underlying logic can be explained simply and I would just use five stages to explain the process.

First is all the stillbirth data are brought together, as in all the large global data sets are assembled.

I did, and I'm so glad we're doing this one.

It's the story of Dr. Christopher Murray, who created the global burden of disease study.

Basically, he wanted to know what actually makes people sick and kills them everywhere, not just in rich countries.

And that turned out to be a huge deal.

It gives you a ratio.

But the textbook notes that newer, massive epidemiological projects like the Global Burden of Disease Study are shifting towards YLLs.

Why the shift? I mean, what does a YLL tell a clinician that an SMR doesn't?

Well, SMRs are excellent for showing relative risk, but they can obscure the absolute human cost.

For me, I no longer can imagine how it's possible that a mental health care provider cannot be versed in some way I think they are now going to become integral to helping our patients, if not only to treat their existing comorbidity, which is on label, but if these data can be replicated, if these data are epistemically accurate which i think they are which means are they truly accurate i think they are because we see this in the general population with these drugs that they lower mortality so this is not some type of finding that's far reached you know removed from what we already know from these drugs i think it's transformative john i really do i think it's potentially transformative if we can have a treatment that can not only prolong the lifespan of our patients, but also help the health span.

And just recently in Lancet, the Global Burden of Disease Study published their updated estimate of the disability adjusted life years.

And in many ways, what I can say is The strategic priority of psychiatry is to prolong the health span and the lifespan of our patients, and GLP-1s are helping us in both of these ways that we've never seen before.

It really does seem like a paradigm shift in progress, and this evidence only kind of helps progress that forward.